Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Chemo-Immunotherapy in Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2021
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of nivolumab in primary mediastinal large B-cell lymphoma (PMBCL) (6 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival up to 7 years. Started Oct 2021; status: active, not recruiting.
02
Drugs
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT04759586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04759586.